Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Basimglurant (Primary) ; Basimglurant (Primary)
- Indications Fragile X syndrome; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 15 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 17 Jul 2012 Planned End Date changed from 1 Jun 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 11 May 2012 New trial record